Jane Street’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Jane Street’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,900	Closed	-$2.13M	–	9659
2023 Q2	$2.13M	Sell	20,900 -77,700	-79%	-$7.35M	﹤0.01%	4076
2023 Q1	$8.96M	Sell	98,600 -3,800	-4%	-$223K	﹤0.01%	1756
2022 Q4	$3.89M	Sell	102,400 -20,500	-17%	-$705K	﹤0.01%	2829
2022 Q3	$3.09M	Buy	122,900 +105,100	+590%	+$2.91M	﹤0.01%	3407
2022 Q2	$541K	Sell	17,800 -72,000	-80%	-$2.15M	﹤0.01%	6603
2022 Q1	$2.94M	Buy	89,800 +56,800	+172%	+$1.69M	﹤0.01%	4008
2021 Q4	$870K	Sell	33,000 -22,200	-40%	-$1.72M	﹤0.01%	6186
2021 Q3	$5.55M	Buy	55,200 +8,200	+17%	+$961K	﹤0.01%	2576
2021 Q2	$6.65M	Sell	47,000 -9,100	-16%	-$1.03M	﹤0.01%	2238
2021 Q1	$5.59M	Buy	56,100 +37,800	+207%	+$4.41M	﹤0.01%	2255
2020 Q4	$2.26M	Sell	18,300 -25,600	-58%	-$3.36M	﹤0.01%	3276
2020 Q3	$4.28M	Buy	43,900 +31,900	+266%	+$3.99M	﹤0.01%	2022
2020 Q2	$1.87M	Sell	12,000 -42,000	-78%	-$6.38M	﹤0.01%	3160
2020 Q1	$7.79M	Buy	54,000 +52,100	+2,742%	+$10.1M	0.01%	915
2019 Q4	$388K	Buy	+1,900	New	+$347K	﹤0.01%	3984

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jane Street's RETA Position: Q3 2023 in Review

Jane Street sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 70,516 shares — an estimated $7.19M sold.

Jane Street first reported a position in RETA in Q1 2019 and held it in 15 quarters. The position peaked at $8.04M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Jane Street reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Jane Street sold 70,516 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $7.19M.
Jane Street first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 15 quarters.
Jane Street's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8.04M in Q2 2020.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Jane Street's 13F filing for Q3 2023, filed 15 Nov 2023.